Literature DB >> 9295227

Influence of fasting and neuropeptide Y on the suppressive food intake induced by intracerebroventricular injection of glucagon-like peptide-1 in the neonatal chick.

M Furuse1, M Matsumoto, R Mori, K Sugahara, K Kano, S Hasegawa.   

Abstract

Recently, we have reported that central administration of glucagon-like peptide-1 (GLP-1) strongly decreased food intake of chicks. The aim of the present study was to elucidate whether suppressed food intake by central injection of GLP-1 would be modified by an appetite stimulant such as fasting and neuropeptide Y (NPY). Birds (2 days old) were starved for 3 or 6 h and then GLP-1 (0.03 microg/10 microl) or saline was injected by the intracerebroventricular (i.c.v.) route. Birds starved for 6 h ate significantly more food than those starved for 3 h, while irrespective of the time for fasting GLP-1 strongly inhibited food intake as rapidly as 10 min after i.c.v injection. The suppressive effect on food intake continued until 4 h after injection. Central administration of NPY (2.5 microg/10 microl) greatly enhanced food intake, but co-injection of GLP-1 (0.01, 0.02 or 0.03 microg/10 microl) decreased food intake in a dose-dependent fashion. Under GLP-1 (0.03 microg/10 microl) treatment, whether NPY modifies food intake of chicks in a dose-dependent manner was investigated by co-injection of graded levels of NPY (0.4, 1.0 and 2.5 microg/10 microl). GLP-1 completely inhibited the effect of NPY on food intake without a dose response. These results suggest that central GLP-1 may interact with NPY and may be the most potent inhibitor of food intake in the chicken.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9295227     DOI: 10.1016/s0006-8993(97)00623-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

Review 1.  Hypothalamic control of energy and glucose metabolism.

Authors:  Stephanie Sisley; Darleen Sandoval
Journal:  Rev Endocr Metab Disord       Date:  2011-09       Impact factor: 6.514

Review 2.  Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions.

Authors:  Kirsteen N Browning; R Alberto Travagli
Journal:  Compr Physiol       Date:  2014-10       Impact factor: 9.090

Review 3.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

Review 4.  Regulation of appetite to treat obesity.

Authors:  Gilbert W Kim; Jieru E Lin; Michael A Valentino; Francheska Colon-Gonzalez; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

5.  Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity.

Authors:  Michael A Valentino; Francheska Colon-Gonzalez; Jieru E Lin; Scott A Waldman
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

Review 6.  Is the GLP-1 system a viable therapeutic target for weight reduction?

Authors:  Jenny Tong; Darleen A Sandoval
Journal:  Rev Endocr Metab Disord       Date:  2011-09       Impact factor: 6.514

Review 7.  CNS GLP-1 regulation of peripheral glucose homeostasis.

Authors:  Darleen Sandoval
Journal:  Physiol Behav       Date:  2008-05-27

8.  Type-dependent differential expression of neuropeptide Y in chicken hypothalamus (Gallus domesticus).

Authors:  Gui-Qian Chen; Xiu-Fang Hu; Kunio Sugahara; Ji-Shuang Chen; Xue-Mei Song; Hui-Chao Zheng; Yong-Qing Jiang; Xin Huang; Jun-Fang Jiang; Wei-Dong Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2007-11       Impact factor: 3.066

9.  Exendin-4 antagonizes the metabolic action of acylated ghrelinergic signaling in the hypothalamic paraventricular nucleus.

Authors:  Shayan Abtahi; Erin Howell; Jack T Salvucci; Joshua M R Bastacky; David P Dunn; Paul J Currie
Journal:  Gen Comp Endocrinol       Date:  2018-10-15       Impact factor: 2.822

10.  Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism.

Authors:  Elena Ceccarelli; Elisa G Guarino; Daniela Merlotti; Aurora Patti; Luigi Gennari; Ranuccio Nuti; Francesco Dotta
Journal:  Front Endocrinol (Lausanne)       Date:  2013-06-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.